Genetic overlap between sarcoidosis and lung cancer: a combined in silico and in vitro approach

Abstract Sarcoidosis patients exhibit an elevated risk of developing lung cancer (LC), suggesting shared genetic and molecular mechanisms between these conditions. This study aimed to identify common differentially expressed genes (DEGs) in sarcoidosis and LC and to evaluate the therapeutic potentia...

Full description

Saved in:
Bibliographic Details
Main Authors: Sanjukta Dasgupta, Moupiya Ghosh, Subhendu Chakrabarty, Gopal Chakrabarti, Amlan Das
Format: Article
Language:English
Published: BMC 2025-08-01
Series:Hereditas
Subjects:
Online Access:https://doi.org/10.1186/s41065-025-00503-7
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849235095181852672
author Sanjukta Dasgupta
Moupiya Ghosh
Subhendu Chakrabarty
Gopal Chakrabarti
Amlan Das
author_facet Sanjukta Dasgupta
Moupiya Ghosh
Subhendu Chakrabarty
Gopal Chakrabarti
Amlan Das
author_sort Sanjukta Dasgupta
collection DOAJ
description Abstract Sarcoidosis patients exhibit an elevated risk of developing lung cancer (LC), suggesting shared genetic and molecular mechanisms between these conditions. This study aimed to identify common differentially expressed genes (DEGs) in sarcoidosis and LC and to evaluate the therapeutic potential of a repurposable drug targeting these shared genes. Gene expression datasets (GSE157671 and GSE229253) were analyzed to identify overlapping DEGs, with validation performed using additional GEO datasets and the GEPIA tool. Functional enrichment and protein–protein interaction (PPI) analyses were conducted using Enrichr and STRING, while associated miRNAs and transcription factors were identified via miRNet. Twelve DEGs—SALL4, WNT10A, RASAL1, CAMK2B, GADD45B, KLF4, OLR1, CSF3, WIF1, RAMP3, AGER, and PRKAG3—were consistently dysregulated in both diseases. These genes were significantly associated with epithelial cell enrichment and the Wnt signaling pathway. Drug–gene interaction analysis using DGIdb prioritized metformin as a candidate drug targeting PRKAG3. Its structural integrity was confirmed via X-ray diffraction (XRD) and Rietveld refinement. In vitro validation using MTT assays revealed that metformin selectively reduced viability in A549 (adenocarcinoma human alveolar basal epithelial cells) and HeLa (a widely used epithelial cancer cell line), with minimal cytotoxicity in WI38 normal lung fibroblasts. Colony formation assays further demonstrated dose-dependent, long-term growth inhibition in cancer cells, corroborated by observable morphological alterations. Overall, this study highlights shared pathogenic signatures between sarcoidosis and LC and proposes metformin as a promising therapeutic candidate. These findings support the rationale for drug repurposing and the development of targeted therapies for patients with overlapping disease profiles or those at increased risk of LC progression from sarcoidosis.
format Article
id doaj-art-84d32f54188743e3bbc52d080ad120a2
institution Kabale University
issn 1601-5223
language English
publishDate 2025-08-01
publisher BMC
record_format Article
series Hereditas
spelling doaj-art-84d32f54188743e3bbc52d080ad120a22025-08-20T04:02:55ZengBMCHereditas1601-52232025-08-01162111610.1186/s41065-025-00503-7Genetic overlap between sarcoidosis and lung cancer: a combined in silico and in vitro approachSanjukta Dasgupta0Moupiya Ghosh1Subhendu Chakrabarty2Gopal Chakrabarti3Amlan Das4Department of Biotechnology, Center for Multidisciplinary Research & Innovations, Brainware UniversityDepartment of Basic Science and Humanities, Institute of Engineering and Management (IEM), Kolkata, University of Engineering and ManagementDepartment of Biotechnology and Dr. B.C. Guha Centre for Genetic Engineering and Biotechnology, University of CalcuttaDepartment of Biotechnology and Dr. B.C. Guha Centre for Genetic Engineering and Biotechnology, University of CalcuttaDepartment of Microbiology, Royal School of Biosciences, The Assam Royal Global UniversityAbstract Sarcoidosis patients exhibit an elevated risk of developing lung cancer (LC), suggesting shared genetic and molecular mechanisms between these conditions. This study aimed to identify common differentially expressed genes (DEGs) in sarcoidosis and LC and to evaluate the therapeutic potential of a repurposable drug targeting these shared genes. Gene expression datasets (GSE157671 and GSE229253) were analyzed to identify overlapping DEGs, with validation performed using additional GEO datasets and the GEPIA tool. Functional enrichment and protein–protein interaction (PPI) analyses were conducted using Enrichr and STRING, while associated miRNAs and transcription factors were identified via miRNet. Twelve DEGs—SALL4, WNT10A, RASAL1, CAMK2B, GADD45B, KLF4, OLR1, CSF3, WIF1, RAMP3, AGER, and PRKAG3—were consistently dysregulated in both diseases. These genes were significantly associated with epithelial cell enrichment and the Wnt signaling pathway. Drug–gene interaction analysis using DGIdb prioritized metformin as a candidate drug targeting PRKAG3. Its structural integrity was confirmed via X-ray diffraction (XRD) and Rietveld refinement. In vitro validation using MTT assays revealed that metformin selectively reduced viability in A549 (adenocarcinoma human alveolar basal epithelial cells) and HeLa (a widely used epithelial cancer cell line), with minimal cytotoxicity in WI38 normal lung fibroblasts. Colony formation assays further demonstrated dose-dependent, long-term growth inhibition in cancer cells, corroborated by observable morphological alterations. Overall, this study highlights shared pathogenic signatures between sarcoidosis and LC and proposes metformin as a promising therapeutic candidate. These findings support the rationale for drug repurposing and the development of targeted therapies for patients with overlapping disease profiles or those at increased risk of LC progression from sarcoidosis.https://doi.org/10.1186/s41065-025-00503-7SarcoidosisLung cancerMetforminDifferentially expressed genesX-ray diffraction
spellingShingle Sanjukta Dasgupta
Moupiya Ghosh
Subhendu Chakrabarty
Gopal Chakrabarti
Amlan Das
Genetic overlap between sarcoidosis and lung cancer: a combined in silico and in vitro approach
Hereditas
Sarcoidosis
Lung cancer
Metformin
Differentially expressed genes
X-ray diffraction
title Genetic overlap between sarcoidosis and lung cancer: a combined in silico and in vitro approach
title_full Genetic overlap between sarcoidosis and lung cancer: a combined in silico and in vitro approach
title_fullStr Genetic overlap between sarcoidosis and lung cancer: a combined in silico and in vitro approach
title_full_unstemmed Genetic overlap between sarcoidosis and lung cancer: a combined in silico and in vitro approach
title_short Genetic overlap between sarcoidosis and lung cancer: a combined in silico and in vitro approach
title_sort genetic overlap between sarcoidosis and lung cancer a combined in silico and in vitro approach
topic Sarcoidosis
Lung cancer
Metformin
Differentially expressed genes
X-ray diffraction
url https://doi.org/10.1186/s41065-025-00503-7
work_keys_str_mv AT sanjuktadasgupta geneticoverlapbetweensarcoidosisandlungcanceracombinedinsilicoandinvitroapproach
AT moupiyaghosh geneticoverlapbetweensarcoidosisandlungcanceracombinedinsilicoandinvitroapproach
AT subhenduchakrabarty geneticoverlapbetweensarcoidosisandlungcanceracombinedinsilicoandinvitroapproach
AT gopalchakrabarti geneticoverlapbetweensarcoidosisandlungcanceracombinedinsilicoandinvitroapproach
AT amlandas geneticoverlapbetweensarcoidosisandlungcanceracombinedinsilicoandinvitroapproach